Earnings Call · Q4 FY2021·2022-03-17

Q4 21EPS +45.00%·Rev n/aQ3 21EPS +54.35%·Rev n/aQ2 21EPS 0.00%·Rev n/aQ1 21EPS n/a·Rev n/a⚠ consensus missing

Acurx Pharmaceuticals, Inc. ACXP

Rob Shawah — Chief Financial Officer

David Luci — Chief Executive Officer

+1.3%1d on move date+0.1% vs SPY3d−8.1%5d−1.9%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACXP calls or request research access.

More ACXP calls Browse calls Request research access